Topiramate (Epilepsy)

Urinary malformations

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12871
R48606		 Thomas (Topiramate) (Controls exposed to Lamotrigine, sick), 2021 Urinary malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 1.90 [0.07;50.68] C
excluded (control group) 		0/9   1/50 1 9
ref
S12872
R48616		 Thomas (Topiramate) (Controls unexposed, sick), 2021 Urinary malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 3.02 [0.16;58.01] C 0/9   6/340 6 9
ref
S7662
R22682		 Tomson (Topiramate), 2018 Renal malformations at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 0.97 [0.06;16.93] C 0/152   8/2,514 8 152
ref
Total 2 studies 1.68 [0.22;13.11] 14 161
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Thomas (Topiramate) (Controls unexposed, sick), 2021Thomas, 2021 1 3.02[0.16; 58.01]6948%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Tomson (Topiramate), 2018Tomson, 2018 2 0.97[0.06; 16.93]815252%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 1.68[0.22; 13.11]141610.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate) (Controls unexposed, sick; 2: Topiramate;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.68[0.22; 13.11]141610%NAThomas (Topiramate) (Controls unexposed, sick), 2021 Tomson (Topiramate), 2018 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 3.02[0.16; 58.01]69 -NAThomas (Topiramate) (Controls unexposed, sick), 2021 1 exposed to other treatment, sickexposed to other treatment, sick 0.97[0.06; 16.93]8152 -NATomson (Topiramate), 2018 1 Tags Adjustment   - No  - No 1.68[0.22; 13.11]141610%NAThomas (Topiramate) (Controls unexposed, sick), 2021 Tomson (Topiramate), 2018 2 All studiesAll studies 1.68[0.22; 13.11]141610%NAThomas (Topiramate) (Controls unexposed, sick), 2021 Tomson (Topiramate), 2018 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12871

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 3.02[0.16; 58.01]69 -NAThomas (Topiramate) (Controls unexposed, sick), 2021 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.30[0.15; 11.21]91610%NAThomas (Topiramate) (Controls exposed to Lamotrigine, sick), 2021 Tomson (Topiramate), 2018 20.510.01.0